Home > Boards > US Listed > Biotechs > Verastem (VSTM)

Verastem Oncology to Present at the H.C. Wainwright

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
stockguard Member Profile
 
Followed By 15
Posts 1,247
Boards Moderated 0
Alias Born 07/09/05
160x600 placeholder
Verastem Oncology Announces Dosing of First Patient in Yakult Honsha Co., Ltd.’s Japanese Bridging Study Evaluating COPIKTR... Business Wire - 10/7/2019 7:00:00 AM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 10/4/2019 7:00:00 AM
Verastem Oncology Receives Orphan Drug Designation from FDA for COPIKTRA for the Treatment of T-Cell Lymphoma Business Wire - 10/3/2019 2:25:00 PM
Verastem Oncology Presents New Preclinical Duvelisib Data at the 5th International Conference on New Concepts in Lymphoid Mal... Business Wire - 10/3/2019 7:00:00 AM
Verastem Oncology to Present at the Cantor 2019 Global Healthcare Conference Business Wire - 9/26/2019 7:00:00 AM
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the 18th Annual International Workshop on Chronic Lympho... Business Wire - 9/20/2019 1:00:00 PM
Verastem Oncology to Present at the 21st Annual H.C. Wainwright Global Investment Conference Business Wire - 9/3/2019 4:05:00 PM
Verastem Oncology Announces COPIKTRA™ (Duvelisib) Presentations at the Society of Hematologic Oncology 2019 Annual Meeting Business Wire - 9/3/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/1/2019 5:09:51 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 4:06:59 PM
Verastem Oncology Reports Second Quarter 2019 Financial Results and Highlights Recent Company Progress Business Wire - 8/1/2019 4:05:00 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 7/31/2019 7:43:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/29/2019 4:17:25 PM
Verastem Oncology Appoints Brian Stuglik as Chief Executive Officer Business Wire - 7/29/2019 4:05:00 PM
Verastem in Licensing Agreement with Sanofi; Shares Up Dow Jones News - 7/25/2019 5:31:00 PM
Verastem Oncology Signs an Exclusive License Agreement with Sanofi for the Development & Commercialization of COPIKTRA® (duv... Business Wire - 7/25/2019 4:05:00 PM
Verastem Oncology to Announce Second Quarter 2019 Financial Results and Corporate Update on August 1, 2019 Business Wire - 7/25/2019 7:00:00 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 7/10/2019 4:29:18 PM
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Business Wire - 7/3/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2019 5:12:40 PM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data in Peripheral T-Cell Lymphoma at the 2019 International Conference on... Business Wire - 6/21/2019 7:00:00 AM
Verastem Oncology Announces Leadership Changes Business Wire - 6/20/2019 7:00:00 AM
Verastem Oncology Presents COPIKTRA™ (Duvelisib) Data at the European Hematology Association 2019 Annual Meeting Business Wire - 6/17/2019 7:00:00 AM
Verastem Oncology to Present at the Jefferies 2019 Global Healthcare Conference Business Wire - 5/30/2019 7:00:00 AM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/20/2019 5:23:17 PM
stockguard   Tuesday, 04/02/19 01:04:04 PM
Re: None
Post # of 464 
Verastem Oncology to Present at the H.C. Wainwright Global Life Sciences Conference
Tue April 2, 2019 7:00 AM|Business Wire|About: VSTM
BOSTON--(BUSINESS WIRE)-- Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, today announced that the Company will present at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 11:50 a.m. BST in London, UK.

A live webcast of the presentation will be available on the investors section of the Company’s website at www.verastem.com. An archived presentation will be available for 90 days.

About Verastem Oncology

Verastem Oncology (Nasdaq:VSTM) is a commercial biopharmaceutical company committed to the development and commercialization of medicines to improve the lives of patients diagnosed with cancer. We are driven by the strength, tenacity and courage of those battling cancer – single-minded in our resolve to deliver new therapies that not only keep cancer at bay, but improve the lives of patients diagnosed with cancer. Because for us, it’s personal.

Our first FDA approved product is now available for the treatment of patients with certain types of indolent non-Hodgkin’s lymphoma (iNHL). Our pipeline comprises product candidates that seek to treat cancer by modulating the local tumor microenvironment. For more information, please visit www.verastem.com.

https://cts.businesswire.com/ct/CT?id=bwnews&sty=20190402005118r1&sid=acqr7&distro=nx&lang=en

View source version on businesswire.com: https://www.businesswire.com/news/home/20190402005118/en/

Verastem Oncology:
Rob Gagnon
Chief Financial Officer
+1 781-469-1681
rgagnon@verastem.com

Investors:
Joseph Rayne
Argot Partners
+1 617-340-6075
joseph@argotpartners.com

Source: Verastem, Inc.

Copyright Business Wire 2019

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist